Trial
NCT04429321
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
—
Condition
Renal Cell Carcinoma
Intervention
Nivolumab
Why stopped
failure to accrue
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-26